Equity Details
Price & Market Data
Price: $1.21
Daily Change: -$0.05 / 4.13%
Daily Range: $1.21 - $1.28
Market Cap: $51,624,928
Daily Volume: 18,449
Performance Metrics
1 Week: -13.97%
1 Month: -30.86%
3 Months: -12.32%
6 Months: -58.70%
1 Year: 18.63%
YTD: -22.44%
About Estrella Immunopharma, Inc. (ESLA)
Find all you need to know about Estrella Immunopharma, Inc. (ESLA)'s market performance. The stock is valued at 1.21, showing a daily change of -$0.05 / 4.13%. Its market capitalization is 51,624,928. Dive into its short-term and long-term performance trends.
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.